The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains…
Heidelberg, Germany – May 31, 2019 – Molecular Health (MH), a leading company in the field of data science for precision medicine, today announced that the Company…
Heidelberg, Germany – Tuesday, May 7, 2019–Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of…
Klicken Sie auf den unteren Button, um den Inhalt von www.linkedin.com zu laden.
Over the last decade, Dataome has grown to become one of the largest globally available resources of clinico-molecular data and knowledge. From millions of patient lives to hundreds of billions of molecular data points, it provides a single-point of access to the worlds biomedical knowledge through our decision support applications.
Molecular Health Predict (MH Predict) is an application to predict clinical trials probabilities of success. It enables the improvement of clinical trial success and reduces clinical trial failure while optimizing resource allocation for the biopharma industry and investors and enhancing the overall efficiency of drug development.
Molecular Health Guide Mendel (MH Mendel) supports human geneticists in diagnosing hereditary diseases and creating diagnostic reports for individual patients. The germline data analysis follows official genetic guidelines and uses ACMG variant classification criteria.
Molecular Health Guide (MH Guide) identifies safe and effective therapies for cancer patients by analyzing the cancer’s molecular profile. It matches detected mutations to the world’s knowledge in the field of oncology and helps medical experts to create a patient-specific clinical report with treatment recommendations.
Molecular Health Guide BRCA (MH BRCA) supports medical professionals in identifying and reporting clinically significant germline variants following official genetic guidelines. Create individual patient reports based on NGS data from BRCA1/BRCA2 and other genes associated with hereditary breast and ovarian cancer syndrome.
Molecular Health’s growing number of customers and partnerships include some of the best hospitals, laboratories, universities, and genetic facilities in the world.
To find out more, you can call our customer service or send us an e-mail. We would be delighted to provide you with more information or answer your questions.
E-mail: CustomerCareUS@molecularhealth.com
